Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Example Input: Besides holding a rare special session, the full Legislature will meet in a way unlike ever before. A small number of lawmakers will meet in the state Capitol in Cheyenne and the rest will take part by video conference. Lawmakers have drafted five bills, four of which have mirror versions so the House and Senate can consider them simultaneously, and plan to wrap up no later than Saturday. The bills would: — Give Gov. Mark Gordon guidance in allocating $1.25 billion in federal Coronavirus Aid Relief and Economic Security (CARES) Act funding. Legislators propose putting the money toward emergency public health costs, aid for families and businesses, economic development programs including infrastructure projects and, to the extent federal law allows, replacing public revenue lost during the pandemic. — Help ensure that people who fall ill from the coronavirus can collect unemployment benefits and not be evicted for missing rent payments. — Alter state funding calculations for school districts and authorize Gordon to make certain emergency funding transfers between state agencies. — Allocate up to $275 million in interest-free loans and other aid for businesses affected by the coronavirus. — Give legal immunity to businesses whose customers contract the coronavirus, a proposal to be initially taken up by the Senate only. The public can monitor the proceedings online. Journalists will keep an eye on things from the House and Senate galleries. Wyoming’s previous special session in 2004 involved an ultimately unsuccessful constitutional amendment to limit payouts in medical malpractice cases.
Example Output: Rare Wyoming Legislature special session to take on COVID-19.

Example Input: Alexis Shapiro suffered damage to her pituitary gland, which helps regulate weight, as a result of the brain disease. She has gained about 140 pounds (63.5 kgs) in less than two years because of the problem, her mother said. Her extreme excess of body fat is clinically defined as morbid obesity. “It has been heartbreaking for her and for us. She cannot do the things she used to love,” Jennifer Shapiro, her mother, said on the fundraising site GoFundMe. The mother said she is seeking about $50,000 for life-saving surgery to reduce the size of her daughter’s stomach because the family’s insurance company will not pay for the procedure unless the patient is at least 18 or has achieved full bone growth. Dr. Thomas Inge, a specialist in pediatric obesity at the Cincinnati Children’s Hospital Medical Center, told NBC News that Alexis could receive the surgery at the hospital where he works within six weeks now that the funding appears to be in place. “Alexis will be seen this week in Cincinnati, and the preparations for surgery will be made at that time,” Inge told Reuters by email.
Example Output: Donors pitch in to pay for surgery for extremely obese Texas girl.

Example Input: File photo shows a young carer holding the hands of an elderly woman in a residential home for the elderly in Planegg near Munich June 19, 2007. REUTERS/Michaela Rehle The study, reported on Sunday in the journal BioMed Central BMC Neurology, involved 12 patients who had greatly improved language recall shortly after treatment with Enbrel, or etanercept, an anti-inflammatory drug co-marketed by Amgen and Wyeth. “We often see verbal effects within a few minutes of the first dose,” said Dr. Edward Tobinick, director of the Institute for Neurological Research, a private medical group inc., in Los Angeles, who led the study. Tobinick invented and holds several patents on a special method of injecting the drug into the neck. He said he charges anywhere between $10,000 and $40,000 per patient for the treatments. In January, Tobinick’s report on a single patient, and release of a striking video, drew the attention of the Alzheimer’s Association, which released a statement expressing concern. “People with Alzheimer’s and their families may place undue value on this new finding based on the dramatic language used in its description and the apparent immediate effect,” the group said. “We need to see work in other laboratories by scientists without financial interest in the product,” it added. Dr. Sam Gandy, chairman of the Alzheimer’s Association’s medical and science council, said the latest study, done at Tobinick’s clinic, does not offer that independent confirmation. “It’s still not a proper trial,” Gandy said. Tobinick believes the drug may work in the brain by blocking an excess of tumor necrosis factor-alpha or TNF-alpha, which may affect communication in the brain. The study looked at language difficulties, such as in finding words, in 12 patients with mild-to-severe Alzheimer’s disease who were administered etanercept weekly for six months. “There was a significant improvement in the majority of the verbal measures that were studied. The remainder showed a tendency toward improvement, which was not significant,” Tobinick said in a telephone interview. He said the study provides evidence that “excess TNF, in the Alzheimer brain, may offer a new way to address this language dysfunction.”   Tobinick acknowledged the study is limited because people knew they were getting the drug. Alzheimer’s patients in such open-label studies often show improvement. “Placebo effect is an enormous problem in open-label studies,” said Dr. Scott Turner, incoming director of the Memory Disorders Program at Georgetown University Medical Center in Washington. Turner said the true test must come from a more scientifically rigorous double-blind, placebo-controlled, randomized clinical trial. In such studies, patients receive either a dummy treatment or an active agent, and neither the doctor nor the patient knows which. Amgen has also expressed concern about the research, claiming there has been insufficient evidence so far. “This off-label, unapproved treatment, administered by Dr. Edward Tobinick, is not supported nor endorsed by Amgen,” the company said in April on its Web site. A video showing one woman's response to the drug in a sister study can be found at : here
Example Output:
Drug restores speech in Alzheimer's; experts worry.